Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash
Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan ,.
Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration granted Priority Review for the supplemental Biologics.
Genmab Announces Financial Results for the First Quarter of 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.